Ropeginterferon Alfa-2b for the Treatment of Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes and Chronic Myelomonocytic Leukemia

NCT07468916 · clinicaltrials.gov ↗
PHASE2
Phase
NOT_YET_RECRUITING
Status
35
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Jonsson Comprehensive Cancer Center

Collaborators